[Guidelines for the diagnosis and treatment of pulmonary hypertension]

Rev Mal Respir. 2010 Feb;27(2):141-50. doi: 10.1016/j.rmr.2009.11.013. Epub 2010 Feb 12.
[Article in French]


Introduction: A joint Task Force of the ESC and of the ERS has developed guidelines on the diagnosis and treatment of pulmonary hypertension (PH) to provide updated information on the management of patients with this condition.

State of the art: The term pulmonary hypertension (PH) describes a group of devastating and life-limiting diseases, defined by mean pulmonary artery pressure >25 mmHg at rest. The diagnosis of PH requires a series of investigations intended to confirm the diagnosis, clarify the clinical group and the specific aetiology and an algorithm for this is proposed. Several drugs are currently approved to try to correct endothelial dysfunction. They lead to a significant improvement in the prognosis of patients who are in NYHA functional class II, III or IV. The evaluation of the severity of PH has a pivotal role in the choice of initial treatment and evaluation of the response to therapy in individual patients.

Perspective: These guidelines should be widely disseminated and implemented in order to improve the management of patients with PH.

Conclusion: These guidelines summarise recent advances in the understanding and management of PH.

Publication types

  • Review

MeSH terms

  • Algorithms
  • Antihypertensive Agents / adverse effects
  • Antihypertensive Agents / therapeutic use*
  • Bosentan
  • Carbolines / adverse effects
  • Carbolines / therapeutic use
  • Drug Therapy, Combination
  • Endothelin Receptor Antagonists
  • Europe
  • Evidence-Based Medicine*
  • Humans
  • Hypertension, Pulmonary / classification
  • Hypertension, Pulmonary / diagnosis*
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / etiology
  • Piperazines / adverse effects
  • Piperazines / therapeutic use
  • Practice Guidelines as Topic
  • Purines / adverse effects
  • Purines / therapeutic use
  • Sildenafil Citrate
  • Sulfonamides / adverse effects
  • Sulfonamides / therapeutic use
  • Sulfones / adverse effects
  • Sulfones / therapeutic use
  • Tadalafil
  • Vasodilator Agents / adverse effects
  • Vasodilator Agents / therapeutic use


  • Antihypertensive Agents
  • Carbolines
  • Endothelin Receptor Antagonists
  • Piperazines
  • Purines
  • Sulfonamides
  • Sulfones
  • Vasodilator Agents
  • Tadalafil
  • Sildenafil Citrate
  • Bosentan